Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

1.8K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.8K
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

209
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
209
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

1.4K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.4K
Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

148
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
148
Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

11.4K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
11.4K
Coagulation01:09

Coagulation

9.4K
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
9.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The association between interhospital transfer and sepsis guideline adherence among rural emergency department patients.

PloS one·2026
Same author

Consensus Recommendations for Clinical Pharmacist Integration into the Acute Stroke Care Team: Endorsed by the American College of Clinical Pharmacy, Neurocritical Care Society, Society for Academic Emergency Medicine, and Society of Critical Care Medicine, and affirmed by the American Academy of Neurology.

Journal of the American College of Clinical Pharmacy : JACCP·2026
Same author

A multi-center retrospective cohort study of SUGAmmadex for neuromuscular blockade reversal in the emergency department: SUGARED study - on behalf of EMPHARM-NET Investigators.

The American journal of emergency medicine·2026
Same author

Minimal Fibrinolysis After Acute Intracerebral Hemorrhage Undercuts the Mechanism of Tranexamic Acid.

Journal of the American Heart Association·2026
Same author

Emergency Medicine Funding Within NIH Is the Least Concentrated of Any Specialty.

Academic emergency medicine : official journal of the Society for Academic Emergency Medicine·2026
Same author

Evaluation of Emergency Medicine Pharmacist Participation in Time to Oral Anticoagulation Reversal: A Systematic Review and Meta-Analysis.

Journal of the American College of Clinical Pharmacy : JACCP·2026

Related Experiment Video

Updated: Dec 21, 2025

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

19.3K

Emergent Warfarin Reversal With Fixed-Dose 4-Factor Prothrombin Complex Concentrate.

Brianna Jansma1, Josephine Montgomery1, Scott Dietrich2

  • 1University of Iowa Hospital and Clinics, Iowa City, IA, USA.

The Annals of Pharmacotherapy
|May 19, 2020
PubMed
Summary

A fixed dose of 1500 units of four-factor prothrombin complex concentrate (4FPCC) effectively reverses warfarin, achieving a target INR in most patients without thrombotic events. This study supports exploring alternative 4FPCC dosing for emergent warfarin reversal.

Keywords:
fixed doseprothrombin complex concentratereversalwarfarin

More Related Videos

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

14.2K
Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation
04:37

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

Published on: May 23, 2025

937

Related Experiment Videos

Last Updated: Dec 21, 2025

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

19.3K
Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

14.2K
Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation
04:37

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

Published on: May 23, 2025

937

Area of Science:

  • Pharmacology
  • Critical Care Medicine
  • Hematology

Background:

  • Dosing of four-factor prothrombin complex concentrate (4FPCC) for emergent warfarin reversal is not standardized.
  • Previous studies suggest lower, fixed-dose regimens may be effective and cost-saving.
  • Further research is needed to establish optimal fixed-dose 4FPCC protocols.

Purpose of the Study:

  • To evaluate the efficacy, safety, and cost-effectiveness of a fixed-dose 4FPCC regimen.
  • To assess the achievement of target International Normalized Ratio (INR) levels post-administration.
  • To analyze the incidence of thrombotic events and survival rates.

Main Methods:

  • Retrospective chart review of 64 adult patients requiring emergent warfarin reversal with 4FPCC.
  • Utilized a fixed-dose regimen of 1500 units of 4FPCC.
  • Primary outcomes included post-4FPCC INR ≤1.5 and ≤2.0; secondary outcomes were thrombotic events and survival.

Main Results:

  • 68.8% of patients achieved a post-4FPCC INR ≤1.5, and 95.3% achieved ≤2.0.
  • No thrombotic events were reported within 7 days of 4FPCC administration.
  • The fixed-dose protocol resulted in cost savings exceeding $1000 per patient.

Conclusions:

  • A fixed dose of 1500 units of 4FPCC is effective in achieving target INR for emergent warfarin reversal.
  • This dosing strategy appears safe, with no reported thrombotic events.
  • Findings support the use of fixed-dose 4FPCC regimens as an alternative to package insert dosing.